Skip to main
VSTM

Verastem (VSTM) Stock Forecast & Price Target

Verastem (VSTM) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Verastem Inc is poised for positive growth as its lead candidate, binimetinib, shows improved response rates among earlier line patients, indicating a strong potential for increased real-world efficacy of its pipeline agents. The company benefits from rising physician enthusiasm and a lower rate of treatment discontinuation compared to historical MEK inhibitors, enhancing the likelihood of broader clinical adoption, especially with potential guideline expansions. Additionally, the promising results of VS-7375 in non-small cell lung cancer (NSCLC) and the improved outcomes demonstrated in combinations with other treatments support Verastem's positioning in the competitive KRAS G12D landscape, fostering confidence in its sustainable market growth.

Bears say

Verastem Inc has faced ongoing operating losses since its inception, raising concerns about its potential to achieve profitability in the near future. The company's focus on KRAS inhibitors may be complicated by the lower response rates and adverse associations with KRAS wild-type variants, which could hinder the efficacy of their treatments in certain patient populations. Furthermore, the risk of failing to secure timely regulatory approvals or encountering delays could adversely affect investor confidence and the overall share price, emphasizing the challenging landscape the company is navigating.

Verastem (VSTM) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Verastem and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Verastem (VSTM) Forecast

Analysts have given Verastem (VSTM) a Strong Buy based on their latest research and market trends.

According to 5 analysts, Verastem (VSTM) has a Strong Buy consensus rating as of Apr 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Verastem (VSTM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.